Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Abdom Radiol (NY)
1 Actas Urol Esp (Engl Ed)
1 Ann Glob Health
1 Arch Toxicol
2 BMC Cancer
1 BMC Urol
1 BMJ Case Rep
1 Cancer Drug Resist
1 Cancer Radiother
1 Cancer Treat Res
1 Cancer Treat Res Commun
1 Cancers (Basel)
1 Case Rep Urol
1 Cell Biol Toxicol
1 Cells
1 Cent European J Urol
1 Clin Cancer Res
1 Clin Transl Radiat Oncol
1 Diabetes Metab Res Rev
1 Diagn Pathol
1 Eur J Pharmacol
1 Eur Urol
1 Eur Urol Focus
2 Eur Urol Oncol
1 Front Cell Dev Biol
1 Front Genet
1 Front Immunol
1 Front Mol Biosci
1 Front Pharmacol
1 Front Public Health
1 Hereditas
1 Int Braz J Urol
3 Int J Mol Sci
1 Int J Radiat Oncol Biol Phys
1 Int J Surg Pathol
1 Int J Urol
1 J Cancer Policy
1 J Endourol
1 J Exp Clin Cancer Res
1 J Immunoassay Immunochem
2 J Immunother Cancer
1 J Med Case Rep
1 J Oncol
1 J Proteomics
2 J Urol
1 Lab Invest
1 Mol Biol Rep
1 Mol Biotechnol
1 Nucl Med Commun
1 Nutr Cancer
2 PLoS One
1 Radiol Case Rep
1 Rev Assoc Med Bras (1992)
1 Scand J Urol
1 Sci Rep
1 Surg Endosc
1 Technol Cancer Res Treat
1 Theranostics
1 Transl Androl Urol
1 Transl Cancer Res
1 Trends Cancer
1 Turk Patoloji Derg
1 Undersea Hyperb Med
8 Urol Oncol
2 Vet Comp Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Abdom Radiol (NY)

  1. MOHAMMADINEJAD P, Khandelwal A, Inoue A, Takahashi H, et al
    Utility of an automatic adaptive iterative metal artifact reduction AiMAR algorithm in improving CT imaging of patients with hip prostheses evaluated for suspected bladder malignancy.
    Abdom Radiol (NY). 2022;47:2158-2167.
    PubMed         Abstract available

    Actas Urol Esp (Engl Ed)

  2. GOMEZ-VEIGA F, Alcaraz-Asensio A, Burgos-Revilla JM, Cozar-Olmo FJ, et al
    Advances in urologic oncology "OncoUrology Forum Special Edition": The best of 2020.
    Actas Urol Esp (Engl Ed). 2022;46:214-222.
    PubMed         Abstract available

    Ann Glob Health

  3. LIU J, Song W, Li Y, Wang Y, et al
    Burden of Coronary Heart Disease and Cancer from Dietary Exposure to Inorganic Arsenic in Adults in China, 2016.
    Ann Glob Health. 2022;88:28.
    PubMed         Abstract available

    Arch Toxicol

  4. HSU HT, Lee HL, Cheng HH, Chang CH, et al
    Relationships of multiple metals exposure, global DNA methylation, and urothelial carcinoma in central Taiwan.
    Arch Toxicol. 2022;96:1893-1903.
    PubMed         Abstract available

    BMC Cancer

  5. ZHU L, Liu X, Zhang W, Hu H, et al
    MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
    BMC Cancer. 2022;22:556.
    PubMed         Abstract available

  6. HAO N, Yang D, Liu T, Liu S, et al
    Laminin-integrin a6b4 interaction activates notch signaling to facilitate bladder cancer development.
    BMC Cancer. 2022;22:558.
    PubMed         Abstract available

    BMC Urol

  7. KOGUCHI D, Matsumoto K, Ikeda M, Taoka Y, et al
    Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study.
    BMC Urol. 2022;22:75.
    PubMed         Abstract available

    BMJ Case Rep

  8. HIETALA A, Joutsen J, Vaarala S, Saily M, et al
    A rare and complete response to combination therapy with radiation and nivolumab in a patient with metastatic urothelial cancer.
    BMJ Case Rep. 2022;15.
    PubMed         Abstract available

    Cancer Drug Resist

  9. RAJENDRAN G, Taylor JA 3rd, Woolbright BL
    Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.
    Cancer Drug Resist. 2021;4:69-84.
    PubMed         Abstract available

    Cancer Radiother

  10. LIMKIN EJ, Guerin F, Espenel S, Terlizzi M, et al
    Use of an intravaginal spacer in young girls treated with brachytherapy for bladder neck rhabdomyosarcoma: Dosimetric impact for organs at risk sparing and acute tolerance.
    Cancer Radiother. 2022;26:486-490.
    PubMed         Abstract available

    Cancer Treat Res

  11. LU K, Chiu KY, Cheng CL
    Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
    Cancer Treat Res. 2022;183:201-223.
    PubMed         Abstract available

    Cancer Treat Res Commun

  12. MAR N, Uchio E, Kalebasty AR
    Use of immunotherapy in clinical management of genitourinary cancers - a review.
    Cancer Treat Res Commun. 2022;31:100564.
    PubMed         Abstract available

    Cancers (Basel)

  13. MEDLE B, Sjodahl G, Eriksson P, Liedberg F, et al
    Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

    Case Rep Urol

  14. HAGIMOTO H, Sano T, Kashima S, Yoshino T, et al
    Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture.
    Case Rep Urol. 2022;2022:4586199.
    PubMed         Abstract available

    Cell Biol Toxicol

  15. FENG D, Lv J, Li K, Cao Q, et al
    CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200/CDC25B pathway.
    Cell Biol Toxicol. 2022 May 14. pii: 10.1007/s10565-022-09715.
    PubMed         Abstract available


  16. KOLAT D, Kaluzinska Z, Bednarek AK, Pluciennik E, et al
    Determination of WWOX Function in Modulating Cellular Pathways Activated by AP-2alpha and AP-2gamma Transcription Factors in Bladder Cancer.
    Cells. 2022;11.
    PubMed         Abstract available

    Cent European J Urol

  17. SUDOL D, Widz D, Mitura P, Plaza P, et al
    Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer.
    Cent European J Urol. 2022;75:41-46.
    PubMed         Abstract available

    Clin Cancer Res

  18. BELLMUNT J, de Wit R, Fradet Y, Climent MA, et al
    Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
    Clin Cancer Res. 2022;28:2050-2060.
    PubMed         Abstract available

    Clin Transl Radiat Oncol

  19. MITCHELL A, Ingle M, Smith G, Chick J, et al
    Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac.
    Clin Transl Radiat Oncol. 2022;35:27-32.
    PubMed         Abstract available

    Diabetes Metab Res Rev

  20. TONRY CL, Evans RM, Ruddock MW, Duggan B, et al
    Clinical features and predictive biomarkers for bladder cancer in patients with Type 2 Diabetes presenting with haematuria.
    Diabetes Metab Res Rev. 2022 May 16:e3546. doi: 10.1002/dmrr.3546.
    PubMed         Abstract available

    Diagn Pathol

  21. TAKATA M, Kumagai M, Tsubata Y, Okanemasa Y, et al
    A surgical case of high-grade urothelial carcinoma of the renal pelvis complicated with giant hydronephrosis, giving rise to diagnostic difficulties on a cytological examination.
    Diagn Pathol. 2022;17:47.
    PubMed         Abstract available

    Eur J Pharmacol

  22. LI Y, Youssef SF, Buanz AB
    Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions.
    Eur J Pharmacol. 2022 May 14:175024. doi: 10.1016/j.ejphar.2022.175024.
    PubMed         Abstract available

    Eur Urol

  23. HALL E, Hussain SA, Porta N, Lewis R, et al
    Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
    Eur Urol. 2022 May 13. pii: S0302-2838(22)02265.
    PubMed         Abstract available

    Eur Urol Focus

  24. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum.
    Eur Urol Focus. 2022 May 13. pii: S2405-4569(22)00110.
    PubMed         Abstract available

    Eur Urol Oncol

  25. FISCHER-VALUCK BW, Patel SA, Brenneman RJ, Christodouleas J, et al
    Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy.
    Eur Urol Oncol. 2022;5:246-250.
    PubMed         Abstract available

  26. HENSLEY PJ, Panebianco V, Pietzak E, Kutikov A, et al
    Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations.
    Eur Urol Oncol. 2022 May 14. pii: S2588-9311(22)00066.
    PubMed         Abstract available

    Front Cell Dev Biol

  27. JEONG SH, Ku JH
    Urinary Markers for Bladder Cancer Diagnosis and Monitoring.
    Front Cell Dev Biol. 2022;10:892067.
    PubMed         Abstract available

    Front Genet

  28. GAO X, Cai J
    Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Front Genet. 2022;13:865204.
    PubMed         Abstract available

    Front Immunol

  29. LI J, Cao D, Huang Y, Xiong Q, et al
    The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer.
    Front Immunol. 2022;13:865643.
    PubMed         Abstract available

    Front Mol Biosci

  30. YAN Y, Cao X, Wang Z, Huang Z, et al
    Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer.
    Front Mol Biosci. 2022;9:815290.
    PubMed         Abstract available

    Front Pharmacol

  31. WU J, Li T, Ji H, Chen Z, et al
    VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo.
    Front Pharmacol. 2022;13:874235.
    PubMed         Abstract available

    Front Public Health

  32. XIE Q, Zheng H, Chen Y, Peng X, et al
    Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
    Front Public Health. 2022;10:837854.
    PubMed         Abstract available


  33. WANG C, Liu S, Zhang X, Wang Y, et al
    SKA3 is a prognostic biomarker and associated with immune infiltration in bladder cancer.
    Hereditas. 2022;159:20.
    PubMed         Abstract available

    Int Braz J Urol

    Vesical imaging reporting and data system (VI-RADS) in bladder cancer diagnosis in review in this number of International Brazilian Journal of Urology.
    Int Braz J Urol. 2022;48:607-608.

    Int J Mol Sci

  35. LAI CR, Wang HH, Chang HH, Tsai YL, et al
    Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  36. SHIGETA K, Matsumoto K, Tanaka N, Mikami S, et al
    Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  37. HARLAND N, Maurer FB, Abruzzese T, Bock C, et al
    Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  38. STENMAN J, Wickart-Johansson G, Sundquist F, Nilsson J, et al
    Five-Year Follow-up After Multimodal Treatment Incorporating HDR Brachytherapy for Bladder Prostate Rhabdomyosarcoma in Children.
    Int J Radiat Oncol Biol Phys. 2022;113:355-359.

    Int J Surg Pathol

  39. SHBAIR AT, Yasin AI, Topcu A, Coban G, et al
    Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma.
    Int J Surg Pathol. 2022;30:466-469.
    PubMed         Abstract available

    Int J Urol

  40. FUJITA N, Hatakeyama S, Momota M, Narita T, et al
    Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy.
    Int J Urol. 2022 May 16. doi: 10.1111/iju.14926.
    PubMed         Abstract available

    J Cancer Policy

  41. MICHAELI JC, Boch T, Albers S, Michaeli T, et al
    Socio-economic burden of disease: Survivorship costs for bladder cancer.
    J Cancer Policy. 2022;32:100326.
    PubMed         Abstract available

    J Endourol

  42. MERMIER M, Baron P, Roumiguie M, Bajeot AS, et al
    Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder Carcinoma.
    J Endourol. 2022;36:634-640.
    PubMed         Abstract available

    J Exp Clin Cancer Res

  43. CHI M, Liu J, Mei C, Shi Y, et al
    TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    J Exp Clin Cancer Res. 2022;41:175.
    PubMed         Abstract available

    J Immunoassay Immunochem

  44. M SERAG EL-DIEN M, Fathy Mahmoud S, Alhanafy AM, Mohamed Zanaty F, et al
    Prognostic significance of LRIG2 and LRIG3 proteins in urothelial bladder carcinoma.
    J Immunoassay Immunochem. 2022;43:308-332.
    PubMed         Abstract available

    J Immunother Cancer

  45. QU YY, Sun Z, Han W, Zou Q, et al
    Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
    J Immunother Cancer. 2022;10.
    PubMed         Abstract available

  46. GOMEZ-ROCA C, Cassier P, Zamarin D, Machiels JP, et al
    Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naive or experienced for immune checkpoint blockade.
    J Immunother Cancer. 2022;10.
    PubMed         Abstract available

    J Med Case Rep

  47. FUU T, Iijima K, Kusama Y, Otsuki T, et al
    Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    J Med Case Rep. 2022;16:193.
    PubMed         Abstract available

    J Oncol

  48. LONGJUN C, Jianjun Z, Kun P, Lin H, et al
    NF-kappaB-Activated lncRNACASC9 Promotes Bladder Cancer Progression by Regulating the TK1 Expression.
    J Oncol. 2022;2022:9905776.
    PubMed         Abstract available

    J Proteomics

  49. TANG X, Xiao X, Sun H, Zheng S, et al
    96DRA-Urine: A high throughput sample preparation method for urinary proteome analysis.
    J Proteomics. 2022;257:104529.
    PubMed         Abstract available

    J Urol

  50. HUELSTER HL, Sexton WJ
    Real-World Outcomes Driving the Needle toward Simplification of Nonmuscle Invasive Bladder Cancer Risk Stratification.
    J Urol. 2022 May 2:101097JU0000000000002731. doi: 10.1097/JU.0000000000002731.

  51. KATES M, Mansour AM, Lamm DL, Shore N, et al
    Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer.
    J Urol. 2022 May 16:101097JU0000000000002778. doi: 10.1097/JU.0000000000002778.
    PubMed         Abstract available


  52. CATTO JWF, Khetrapal P, Ricciardi F, Ambler G, et al
    Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.
    JAMA. 2022 May 15. pii: 2792543. doi: 10.1001/jama.2022.7393.
    PubMed         Abstract available

  53. MAGANTY A, Herrel LA, Hollenbeck BK
    Robotic Surgery for Bladder Cancer.
    JAMA. 2022 May 15. pii: 2792544. doi: 10.1001/jama.2022.6417.

    Lab Invest

  54. SHAFI S, Aung TN, Xirou V, Gavrielatou N, et al
    Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
    Lab Invest. 2022 May 17. pii: 10.1038/s41374-022-00796.
    PubMed         Abstract available

    Mol Biol Rep

  55. SINGH R, Singh UP, Agrawal V, Garg M, et al
    Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
    Mol Biol Rep. 2022 May 20. pii: 10.1007/s11033-022-07563.
    PubMed         Abstract available

    Mol Biotechnol

  56. ZHANG W, Zhang J, Hu Z, Sun W, et al
    LncRNA ARAP1-AS1 Promotes Bladder Cancer Development by Regulating the miR-3918/KIF20A Axis.
    Mol Biotechnol. 2022 May 13. pii: 10.1007/s12033-022-00489.
    PubMed         Abstract available

    Nucl Med Commun

  57. GHORBANI H, Soltani S, Zakavi SR, Masoudifard A, et al
    Bone scan with technetium 99m-methyl diphosphonate, the missing link in the initial staging of muscle-invasive bladder carcinoma.
    Nucl Med Commun. 2022 Apr 12. pii: 00006231-990000000-00007.
    PubMed         Abstract available

    Nutr Cancer

  58. GU Y, Zeng J, Zou Y, Liu C, et al
    Folate Intake and Risk of Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Epidemiological Studies.
    Nutr Cancer. 2022;74:1593-1605.
    PubMed         Abstract available

    PLoS One

  59. AGHAMIR SMK, Khatami F, Farrokhpour H, Oliveira Reis L, et al
    Oncologic outcomes of Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis.
    PLoS One. 2022;17:e0267934.
    PubMed         Abstract available

  60. OKORIE CL, Gatsby E, Schroeck FR, Ould Ismail AA, et al
    Using electronic health records to streamline provider recruitment for implementation science studies.
    PLoS One. 2022;17:e0267915.
    PubMed         Abstract available

    Radiol Case Rep

  61. VILARES AT, Nunes Silva C, Correia da Silva M, Sousa J, et al
    Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer.
    Radiol Case Rep. 2022;17:2383-2387.
    PubMed         Abstract available

    Rev Assoc Med Bras (1992)

  62. SARIER M
    Association between human papillomavirus and urothelial carcinoma of the bladder.
    Rev Assoc Med Bras (1992). 2022;68:551-552.

    Scand J Urol

  63. WANG EYH, Pihlstrom N, Malmstrom PU, Gardmark T, et al
    Improved long-term outcome of patients with non-muscle invasive, low and intermediate risk bladder cancer between 1997 and 2014; a Swedish population-based study.
    Scand J Urol. 2022 May 16:1-6. doi: 10.1080/21681805.2022.2062046.
    PubMed         Abstract available

    Sci Rep

  64. LAFORGUE L, Fertin A, Usson Y, Verdier C, et al
    Efficient deformation mechanisms enable invasive cancer cells to migrate faster in 3D collagen networks.
    Sci Rep. 2022;12:7867.
    PubMed         Abstract available

    Surg Endosc

  65. YU CC, Chen CH, Hong JH, Ke HL, et al
    Comparison of oncological outcomes for hand-assisted and pure laparoscopic radical nephroureterectomy: results from the Taiwan Upper Tract Urothelial Cancer Collaboration Group.
    Surg Endosc. 2022;36:4342-4348.
    PubMed         Abstract available

    Technol Cancer Res Treat

  66. LUO Z, Jiao B, Huang T, Zhao H, et al
    What is the Role of the Preoperative Blood-Based Inflammation Biomarkers in the Prognosis of Upper Tract Urothelial Carcinoma With Radical Nephroureterectomy? A Single-Centre Retrospective Study.
    Technol Cancer Res Treat. 2022;21:15330338221095667.
    PubMed         Abstract available


  67. GAITEIRO C, Soares J, Relvas-Santos M, Peixoto A, et al
    Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
    Theranostics. 2022;12:3150-3177.
    PubMed         Abstract available

    Transl Androl Urol

  68. ZENG S, Zhang Z, Xu C
    Large population-based study of upper tract urothelial carcinoma in China may provide further insight into the impact of bladder cancer on upper tract urothelial carcinoma's prognosis in Chinese population.
    Transl Androl Urol. 2022;11:573-574.

    Transl Cancer Res

  69. KONIG F, Pradere B, Grossmann NC, Quhal F, et al
    Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.
    Transl Cancer Res. 2022;11:908-917.
    PubMed         Abstract available

    Trends Cancer

  70. RANTI D, Bieber C, Wang YS, Sfakianos JP, et al
    Natural killer cells: unlocking new treatments for bladder cancer.
    Trends Cancer. 2022 May 14. pii: S2405-8033(22)00073.
    PubMed         Abstract available

    Turk Patoloji Derg

  71. THIRUNAVUKKARASU B, Singh S, Sharma AP, Bal A, et al
    Atrophic Kidney-Like Lesion - Case Report of A Provisional Entity with Brief Review of Literature.
    Turk Patoloji Derg. 2022;38:148-152.
    PubMed         Abstract available

    Undersea Hyperb Med

    Two cases of Bacillus Calmette-Guerin cystitis treated with hyperbaric oxygen.
    Undersea Hyperb Med. 2022;49:191-195.
    PubMed         Abstract available

    Urol Oncol

  73. JONES TD, Cheng L
    Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
    Urol Oncol. 2021;39:286-290.
    PubMed         Abstract available

  74. RAZDAN S, Eilender B, Pfail JP, Garcia M, et al
    Higher preoperative eGFR is a predictor of worse renal function decline after robotic assisted radical cystectomy: Implications for postoperative management.
    Urol Oncol. 2022;40:275.
    PubMed         Abstract available

  75. STANGL-KREMSER J, Muto G, Grosso AA, Briganti A, et al
    The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
    Urol Oncol. 2022;40:243-261.
    PubMed         Abstract available

  76. MING J, Wang Y, Su Z, Wang C, et al
    Annular-shaped stenosis in the ureter: Caution should be taken.
    Urol Oncol. 2022;40:274.
    PubMed         Abstract available

  77. BHARADWAJ M, Kaul S, Fleishman A, Korets R, et al
    Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder.
    Urol Oncol. 2022;40:274.
    PubMed         Abstract available

  78. GARAS SN, McAlpine K, Ross J, Carrier M, et al
    Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer.
    Urol Oncol. 2022 May 14. pii: S1078-1439(22)00116.
    PubMed         Abstract available

  79. SOFTNESS K, Kaul S, Fleishman A, Efstathiou J, et al
    Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Urol Oncol. 2022;40:272.
    PubMed         Abstract available

  80. PIAZZA P, Bravi CA, Puliatti S, Cacciamani GE, et al
    Assessing pentafecta achievement after robot-assisted radical cystectomy and its association with surgical experience: Results from a high-volume institution.
    Urol Oncol. 2022;40:272.
    PubMed         Abstract available

    Vet Comp Oncol

  81. PINARD CJ, Stegelmeier AA, Bridle BW, Mutsaers AJ, et al
    Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients.
    Vet Comp Oncol. 2022;20:427-436.
    PubMed         Abstract available

  82. GEDON J, Kehl A, Aupperle-Lellbach H, von Bomhard W, et al
    BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
    Vet Comp Oncol. 2022;20:449-457.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.